Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity by Hoefflin, Rouven et al.
ARTICLE
Received 21 Jan 2016 | Accepted 4 May 2016 | Published 13 Jun 2016
Spatial niche formation but not malignant
progression is a driving force for intratumoural
heterogeneity
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Matthias Schlesner3, Holger Sültmann12, Markus Hohenfellner8,9, Niels Grabe2 & Stefan Duensing1,8,9
Intratumoural heterogeneity (ITH) is a major cause of cancer-associated lethality. Extensive
genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC). Here
we address the question whether ITH increases with malignant progression and can hence be
exploited as a prognostic marker. Unexpectedly, precision quantitative image analysis reveals
that the degree of functional ITH is virtually identical between primary ccRCCs of the
lowest stage and advanced, metastatic tumours. Functional ITH was found to show a
stage-independent topological pattern with peak proliferative and signalling activities almost
exclusively in the tumour periphery. Exome sequencing of matching peripheral and central
primary tumour specimens reveals various region-specific mutations. However, these
mutations cannot directly explain the zonal pattern suggesting a role of microenvironmental
factors in shaping functional ITH. In conclusion, our results indicate that ITH is an early and
general characteristic of malignant growth rather than a consequence of malignant
progression.
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I
ntratumoural heterogeneity (ITH) is a result of genomic
instability and causes clonal variability that drives malignant
progression, therapy resistance and fatal disease outcome1–3.
Elucidating the causes and consequences of ITH is therefore of
utmost importance not only for cancer diagnosis and prognosis
but also for new therapeutic strategies and personalized cancer
patient management4.
Multiregion exome sequencing studies of clear cell renal cell
carcinoma (ccRCC) have recently underscored the extensive
genomic ITH and branched clonal evolution of this tumour
type5,6. In an initial study involving a widely metastatic ccRCC,
approximately 31% of the somatic mutations detected were
ubiquitous. Approximately 23% were shared between sampling
sites of the primary tumour whereas approximately 21% were
shared between metastatic lesions, or found exclusively in one of
the lesions analysed (‘private mutations’; approximately 25%)5.
Inactivation of the VHL tumour suppressor gene was
ubiquitously detected as expected for a truncal driver alteration.
In a follow-up study6, the high frequency of heterogeneous
mutations with most driver mutations arising in spatially
separated subclones was confirmed. In addition, multiple
subclones in a given tumour region were detected.
These findings raise the possibility that the evolution of tumour
subclones leads to enhanced genomic ITH as a tumour progresses
and that this is reflected by increased functional ITH. In this
scenario, functional ITH as measured by changes in protein
expression or protein phosphorylation could be a prognostic marker.
To test this hypothesis, we used a precision quantitative
imaging approach as well as regional whole-exome sequencing to
characterize ITH in primary ccRCCs of various stages. We did
not detect any significant differences in the extent of functional
and genomic ITH between ccRCC of the lowest stage in
comparison to advanced tumours. However, we unexpectedly
found marked and consistent spatial differences in functional
ITH between the tumour centre and the tumour periphery with
highest proliferation and signalling activities almost exclusively in
the tumour periphery. Using whole-exome sequencing, we
discovered various region-specific mutations, thus underscoring
that genomic ITH also follows a spatial pattern. However, the
periphery-specific mutations could not directly explain the
functional ITH, which underscores the role of microenviron-
mental factors in Intratumoural niche formation. Collectively, our
results suggest that ITH is an early and general characteristic of
primary ccRCCs that does not increase with malignant progres-
sion. They support a model in which Intratumoural niches, most
notably the tumour peripheral zone and the tumour centre,
populated by tumour subclones with unique functional properties
and mutations, are drivers of ITH.
Results
Phenotypic and functional ITH in ccRCC is stage-independent.
For a quantitative image analysis of phenotypic and functional
ITH, four immunohistochemical markers were used as surrogates
for genomic alterations in key signalling pathways in ccRCC.
These included HIF-1a and HIF-2a (VHL inactivation), phos-
pho-mTOR S2448 as well as phospho-S6RP S235/236 (activating
mutations in the PI3K/AKT/mTOR pathway)5. In addition, Ki-67
was included to assess the cellular proliferation (Fig. 1a). Primary
tumours from 30 patients were analysed (Supplementary Table 1),
and staining results were quantified as outlined in Fig. 1b. To
detect changes in the extent of functional ITH associated with
malignant progression, we analysed a spectrum of tumours ranging
from small pT1 (n¼ 9) tumours to advanced pT3/4 tumours
(n¼ 11) with or without lymphatic or distant metastasis. A very
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Figure 1 | Precision quantitative image analysis workflow for the characterization of functional ITH. (a) Representative areas with positive
immunohistochemical (IHC) staining for HIF-1a, HIF-2a, phospho-mTOR S2448, phospho-S6RP S235/236 and Ki-67. Only nuclear HIF-1a and HIF-2a
expression was included in the analysis. Scale bar, 100mm. (b) Overview of the quantitative IHC analysis process using a representative image of a whole-
slide scanned pT1M1 tumour after phospho-mTOR S2448 staining. The image was overlaid with a virtual grid consisting of 1mm2 squares that defines the
tumour regions to be analysed. Non-cancerous tissue was subtracted manually (dark grey) and a positive pixel count was performed on the corrected area.
Positivity per square was expressed as percentage of positive pixels. If a square contained non-tumorous tissue, the positivity was normalized to the
corrected square area. Computed values were depicted as a heat map. Coloured squares represent tumour, whereas open squares indicate completely
non-tumorous areas. Squares defined as peripheral tumour zone are marked by a black line. Scale bar, 1 cm.
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metastasis (n¼ 10) was included with the idea that these tumours
would contain features of more advanced ccRCCs. Since our
intention was to compare small renal tumours with widely
advanced tumours, pT2 RCCs were deliberately excluded.
A total of 9,315 data points were collected from five directly
adjacent histological sections from each of the 30 tumours after
two-dimensional alignment to allow a direct comparison of the
same tumour area. An average of 75 virtual 1mm2 squares per
stained section were analysed using either a positive nuclear
count (PNC) algorithm (HIF-1a, HIF-2a and Ki-67) or a positive
pixel count (PPC) algorithm (phospho-mTOR S2448 and
phospho-S6RP S235/236). The latter algorithm was designed to
measure every pixel per 1mm2 square based on its spectral
characteristics (brown for positive staining versus other colours
for negative staining). Non-cancerous regions were excluded from
quantification. Staining results for each square were expressed as
either percentage positive nuclei or percentage positive pixels. If a
1mm2 square contained non-cancerous tissue, the percentage of
positive pixels was normalized to the reduced area. Staining
results were expressed as percentage positivity per square and
represented as heat maps with negative staining in green and the
highest positivity in red (Fig. 2; note that the highest positivity
reached differed between PNC and PPC). Unexpectedly, a first
comparison of heat maps obtained from tumours of various
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Figure 2 | Functional ITH is independent from tumour stage. Representative heat maps of biomarker expression (HIF-1a, HIF-2a, phospho-mTOR S2448,
phospho-S6RP S235/236 and Ki-67) in different prognostic subgroups. Positivity per square was calculated using the positive nuclear count for HIF-1a,
HIF-2a and Ki-67, and expressed as percentage positive nuclei (% PN). Colours correspond to % PN and range from absent (0% PN; green) to high (100%
PN; red) for HIF-1a and HIF-2a. Ki-67 showed a maximum of 25% PN and thus is represented by a smaller range from 0% PN (green) to 25% PN (red).
Cytoplasmic staining for phospho-mTOR S2448 and phospho-S6RP S235/236 was analysed as shown in Fig. 1 and expressed as percentage positive pixels
(% PP). Note that a square with 25% PP is considered completely positive. White squares represent completely non-cancerous tissue and were excluded
from analysis.
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stages did not indicate any major differences in functional ITH
between tumour subgroups (Fig. 2).
To corroborate this notion, we first analysed expression of
individual markers for each prognostic subgroup (Fig. 3a). No
statistically significant differences were detected when mean
percentages of positive nuclei or pixels per square in pT1M0
tumours were compared with pT1M1 or pT3/T4 tumours
(P40.05, Kruskal–Wallis test for multiple comparisons). This
result was not due to patient selection, since the cancer-specific
survival analysis confirmed the differences in patient prognosis
(Fig. 3b).
Next, we displayed the distribution of the five tissue markers as
histogram plots (Fig. 4). These histograms represent the number
of 1mm2 squares that contained a certain percentage of positive
pixels or positive nuclei. For an analysis of individual marker
distribution, we used the D’Agostino–Pearson omnibus test. This
test measures goodness-of-fit and determines how symmetrical
the distribution of the data is and whether the data distribution
follows a Gaussian distribution. A homogeneous marker
distribution throughout an entire tumour sample would be
reflected in a histogram with a normal, or Gaussian distribution,
and the test would be passed. The D’Agostino–Pearson test does
not only provide information about whether a distribution
follows a Gaussian distribution or not but also calculates P values
to assess the probability that a negative or positive test result is
correct. In total, 72% of the samples were significantly
D’Agostino–Pearson negative (Po0.05; D’Agostino–Pearson
test) and were hence considered to be heterogeneous. Twenty-
eight percentage of the samples passed the test; however, not with
a significant P value (P40.05; D’Agostino–Pearson test;
Supplementary Table 2).
We next sought to directly quantify the degree of functional
ITH in the various prognostic subgroups. To this end,
we used two quantitative scores, the s.d. of the PNCs and
PPCs from all squares of a given tumour sample stained
for a specific marker and the maximum-mean (MAX-m) score.
The latter is particularly useful to identify outlier regions
of positive marker staining within the tumour area analysed.
In addition, we used two established biodiversity indices, the
Shannon and the inverse Simpson index, to characterize
functional ITH.
S.d. and MAX-m scores as well as Shannon and inverse
Simpson indices were calculated for all five markers for each of
the 30 tumour specimens (Fig. 5). No statistically significant
differences between different prognostic subgroups were detected
(P40.05, Kruskal–Wallis test for multiple comparisons). In
addition, we were not able to corroborate a statistically significant
correlation between ITH scores and histological tumour grade
(P40.05; Mann–Whitney U-test; Supplementary Table 3).
In summary, our data indicate that functional ITH exists
already in primary ccRCCs of the lowest stage and does not












































































































































































Figure 3 | Quantification of functional ITH in prognostic ccRCC subgroups. (a) Scatter plots showing median±interquartile range of the mean
percentage positive pixels (phospho-mTOR S2448 and phospho-S6RP S235/236) or mean percentage positive nuclei (HIF-1a, HIF-2a and Ki-67) per
tumour. No statistically significant differences were observed between subgroups (P40.05, Kruskal–Wallis test for multiple comparisons). (b) Kaplan–
Meier cancer-specific survival analysis of the patients.
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ITH is unaffected by changes in signalling cascades. We next
performed a correlation analysis of all markers and tumours
using directly corresponding virtual squares of the adjacent tissue
sections (Supplementary Table 4). In both pT1M0 and pT1M1
tumours, a moderate-to-good positive correlation (r¼ 0.4–0.7;
Spearman’s rank correlation coefficient) for HIF-1a and HIF-2a
as well as co-expression of phospho-mTOR S2448 and phospho-
S6RP S235/236 was found. In addition, there was a negative
correlation (r¼  0.51; Spearman’s rank correlation coefficient)
for HIF-1a and phospho-mTOR S2448 expression in pT1M0
tumours. A negative regulation of mTORC1 by HIF-1a has
previously been reported through the HIF-1a transcriptional
target REDD1 (ref. 7), and it remains to be determined if this is
the underlying mechanism for this observation. Tumours of
pT1M1 stage showed a positive correlation between HIF-1a and
phospho-S6RP S235/236 expression (r¼ 0.51; Spearman’s rank
correlation coefficient). Remarkably, however, none of these
correlations was found in pT3/4 ccRCCs. Instead, there was a
negative correlation between HIF-2a expression and the
proliferation marker Ki-67 (r¼  0.46; Spearman’s rank
correlation coefficient)8. No significant correlations were
detected when all tumours combined were analysed.
Taken together, these results indicate that apparent changes in
tissue marker correlations associated with malignant progression
(highlighted in Supplementary Fig. 1) are not reflected by changes
in functional ITH as determined by our quantitative image
analysis.
Tumour periphery and centre are distinct topological niches.
When we analysed the expression of Ki-67 as a marker of cellular
proliferation, we noticed that proliferating cells were
preferentially found in the tumour periphery (Fig. 6a,b). Markers
indicating an activated PI3K/mTOR pathway were found to
follow this pattern with highest expression in the periphery of the
tumours (Fig. 6c). We therefore systematically analysed all
tumours and defined the peripheral zone as the outermost
squares of each tumour (Fig. 1) and determined the localization
of the square with the peak expression for all markers used
(Fig. 6d). A total of 4,475 peripheral zone and 4,425 central zone
squares were evaluated. We found that in the vast majority of
tumours, the peak marker expression was in the peripheral
tumour zone (Po0.05; Bernoulli trial). The only exception was
the expression of phospho-S6RP S235/236 in pT1M1 tumours,
where the majority of tumours showed a peak expression in the
central zone. This result and the fact that tumours were not
uniformly negative in the centre (Fig. 2) rule out that non-specific
effects of tissue processing are responsible for our findings. When
we compared pT1M0 with pT1M1 and pT3/4 tumours, we did
not find any significant differences between the prognostic sub-
groups with respect to the peripheral and central zone expression
of markers (P40.05, Fisher exact test, two-tailed). Next, we tested
whether an unequal admixture of non-tumorous cells may
account for the topological differences that were detected. Centre
and peripheral zones of 24 tumours were stained for CD31 to
measure microvessel density and CD45 to measure leukocyte
infiltration (Supplementary Fig. 2). No significant differences
between the tumour centre and periphery were detected (P40.05;
Mann–Whitney U-test), thus underscoring that spatial ITH was
not due to the admixture of non-tumorous cells or differences in
intratumoural microvessel density (see also analysis of mutant
allele frequencies below).
These results indicate that the tumour periphery and centre
represent distinct topological niches that differ functionally and
that are retained during malignant progression.
Tumour periphery and centre harbour distinct somatic mutations.
We next sought to corroborate whether the differences between
the tumour periphery and the tumour centre with respect to
functional ITH are based on genetic alterations and/or distinct
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Figure 4 | Heterogeneous expression of markers of functional ITH in prognostic ccRCC subgroups. Cumulative histograms of tumour subgroups
representing the number of squares that contained a certain percentage of positive pixels or positive nuclei are shown. None of the marker distribution
passed the D’Agostino–Pearson omnibus normality test indicating a non-Gaussian distribution and therefore a heterogeneous expression pattern in all
three prognostic subgroups.
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sequencing of eight consecutive ccRCCs with different patholo-
gical stages ranging from pT1 to pT4 (Supplementary Table 5).
The zonal pattern of functional heterogeneity was maintained in
all tumours (Supplementary Fig. 3). Tumour periphery and centre
were macrodissected (Fig. 7a), and whole exomes were sequenced







































































































































































































































































































































































































































Figure 5 | Functional ITH is stage independend as measured by heterogeneity scores and biodiversity indices. (a–d) Scatter plots representing
mean±s.d. and individual values of the heterogeneity scores s.d. (a), MAX-m (b), inverse Simpson index (c) and Shannon index (d) for the indicated
biomarkers and prognostic subgroups.
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truncal driver mutations and recurrently mutated genes and
found a total of 28 mutations in seven known ccRCC driver genes
and pathways (Fig. 7b)9–12. Driver mutations were typically
found in both the peripheral and central tumour areas.
For every patient, single-nucleotide variants (SNVs) detected
only in the respective peripheral zone sample were designated as
peripheral and SNVs detected only in the respective central zone
sample were designated as central. Variants that occurred
recurrently in at least six of the eight patients or that were
dbSNP-associated without clinical context were removed. SNVs
were called functional, when they were nonsynonymous, occurred
within splice sites or lead to gain or loss of stop codons.
For an analysis of mutational signatures, SNVs were grouped
into 96 different categories according to their trinucleotide
context and the type of base exchange as previously described13.
We detected a total of 88 functional SNVs and indels that were
specific for either the peripheral zone or the central zone of the
tumours analysed (Fig. 7c,d). There was no correlation between
the number of centre- or periphery-specific mutations and
tumour stage or grade (Supplementary Table 5).
Whereas the central zone specimens from eight ccRCCs
contained on average 8.5±2.6 (mean±s.e.m.) specific functional
SNVs and indels, the eight peripheral zone specimens contained
on average 2.5±1.2 (mean±s.e.m.) specific functional SNVs.
There were no recurrently mutated genes in the tumour
peripheral zone that could directly explain the consistently higher
proliferation rate and signalling activities detected there. Instead,
mutations were found, for example, in genes involved in
chromatin remodelling (CARM1 and GATA3), DNA replication
and repair (POLQ), and cell migration or cytoskeletal organiza-
tion (TJP1, GSN and ENC1). These results suggest that, despite
the presence of unique mutations in the tumour periphery in six
of eight tumours, the enhanced cellular proliferation and
signalling activity represent mainly functional events. An analysis
of the mutant allele frequencies between the centre and periphery
showed no major differences, thus further supporting the notion
that our findings were not due to unequal admixture of
non-tumorous cells (Supplementary Fig. 4).
To test whether specific mutational processes are active in
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Figure 6 | Topological differences in functional ITH define tumour centre and periphery as distinct spatial niches. (a,b) Heat map and
immunohistochemical staining of a representative ccRCC for Ki-67. A representative picture showing the PNC analysis is shown in (b, left panel). Positive
nuclei are false coloured in red, negative nuclei blue. Scale bar, 1mm. High-power views of squares B9 and B10 immunostained for Ki-67 are shown (b, right
panels). Note the differences in proliferating cells between squares B9 (centre) and B10 (periphery). Scale bar, 100mm. (c) Representative
immunohistochemical stainings for phospho-mTOR S2448 and phospho-S6RP S235/236 in the tumour centre and the tumour periphery. Scale bar,
100mm. (d) Each bar shows the percentage of tumours with peak marker expression in the central (grey bars) versus peripheral (black bars) tumour zone.
Significance was assessed using the Bernoulli trial (*Po0.05, **Po0.01).
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triplet distribution of the SNVs was analysed per patient (Fig. 8a)
and per stratum (Fig. 8b). Pair-wise comparisons of the patient-
specific distributions revealed cosine similarities between 0.107
and 0.477, while the cosine similarity between the merged sets of
central and peripheral SNVs was 0.514 (Fig. 8c), indicating higher
differences in the SNV spectra between the patients than between
the tumour peripheral and central areas.
Taken together, whole-exome sequencing analysis demon-
strates the presence of central and peripheral zone-specific
mutations, while mutational signatures do not differ spatially.
Given the presence of driver mutations in both the peripheral and
central areas and the absence of recurrent mutations in cell cycle
or other signalling-related genes in the peripheral zone speci-
mens, we conclude that the enhanced proliferation rate and
signalling activity in the tumour peripheral zone represent mainly
functional events.
Discussion
Renal cancer is a prototypical example of a tumour entity that is
characterized by extensive genomic ITH5,6. In the present report,
we use quantitative image analysis and whole-exome sequencing
to show that functional as well as genomic ITH can be detected at
similar levels in primary ccRCCs of the lowest stage and
advanced, metastatic tumours. ITH is hence not a result of
malignant progression, but rather represents a feature of
malignant growth per se. To explain these findings, we
demonstrate that functional ITH follows a zonal pattern with
peak proliferative and signalling activities almost exclusively in
the tumour periphery. Genomic ITH was found to follow this
topological pattern, since we detected various periphery- and
centre-specific functional SNVs and indels in our whole-exome
sequencing analysis. Functional and genomic niche formation
may hence represent an early and general consequence of an
uncoordinated, three-dimensional growth of a tumour within the
architectural confinement of an established organ. Since such
niches, that is, tumour centre and periphery, are maintained
during malignant progression, the degree of ITH is comparable
between small and large tumours. Our results provide strong
support for the notion that genomic analyses of cancer need to
take spatial differences into account.
Our whole-exome sequencing results do not contradict
previous studies showing branched and converging evolution in
ccRCC5,6, but they underscore that these evolutionary processes
are shaped by topological niches and overlaid by functional
heterogeneity. The fact that we found periphery-specific
mutations could argue for a model in which tumour subclones
with certain mutations that confer a selective advantage are able
to populate this region (‘clone drives niche’). If the periphery-
specific mutations detected do in fact confer such a growth
advantage remains to be determined. However, the absence of
recurrently mutated genes that would directly explain the
consistently higher proliferative and signalling activity and the
absence of periphery-specific mutations in three tumours suggest
an important role of microenvironmental factors in niche
formation and ITH (‘niche drives clone’). In this scenario, the
enhanced proliferation and signalling activity in the peripheral
zone would represent mainly functional events. A zonal tumour
growth pattern has previously been suggested by mathematical
modelling as well as three-dimensional in vitro co-culture
experiments using breast cancer cells14–16. Since truncal drivers
were predominantly found in both niches, one possible
explanation for our results is that proliferation is limited in the
tumour centre, for example, by spatial or other constraints, and
that these constraints become more relaxed towards the tumour
periphery. How this relaxation is achieved is currently unclear,
but there are several possible scenarios including differences in
the level of oxygen, growth factors, cytokines or interstitial fluid
pressure17. Although we did not detect any significant differences
in microvessel density in vital tumour areas of the centre and the
periphery, it is still possible that local oxygen tension and/or
cytokine/chemokine levels play a role, since vessel density and
nutrient supply are frequently uncoupled in malignant
tumours18. Another possibility is the ‘empty site’ model that
has recently been proposed and in which tumour cells proliferate
preferentially when neighbouring non-tumour cells or the
extracellular matrix14. A third possibility to explain the



































































































































































































































































































































































































































































































































Figure 7 | Whole-exome sequencing reveals distinct mutations in the tumour centre and periphery. (a) Macroscopic view of RCC002 with centre (C)
and periphery (P) labelled as dissected. Scale bar, 1 cm. (b) Map of driver mutations found in the tumour periphery or tumour centre of all samples. Colour
indicates the presence of a mutation (blue, nonsynonymous SNV; lavender, frameshift; cyan, stop gain/loss). Yellow indicates the absence of a mutation.
(c,d) Maps of functional SNVs and indels (blue) specific for the tumour periphery (c) or centre (d).
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Figure 8 | Mutational signatures do not differ between the tumour periphery and the tumour centre. (a,b) Triplet distribution of functional SNVs per
patient (a) and per stratum (b), relative contributions. The x axis indicates the triplet context. (c) Cosine similarities of pair-wise comparisons of the
patient-specific distributions (red histogram) and of the merged sets of central and peripheral SNVs (black vertical line).
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tumour and stroma cells19, which would be favoured in the
tumour peripheral zone. It needs to be emphasized that these
mechanisms may not function independently, but may rather
represent co-operating mechanisms for topological functional
and genomic ITH.
Despite an enhanced proliferation in the tumour periphery, the
distributions of nucleotide exchanges in their triplet contexts were
more similar for the two strata than between the different patients
suggesting that the mutational processes are similar in the tumour
centre and periphery.
Spatial differences in ITH have been reported not only in
ccRCC5,6 but also in other tumour entities such as prostate20–23,
lung24,25 and breast cancer26,27. Although we did not perform
multiregion sequencing and focused on relatively large single
tumour regions instead, our results are in line with studies
showing ITH in ccRCCs of different stage6. Interestingly, the
application of biodiversity scores such as the Shannon or Simpson
index, which are also used in the present study, has previously
shown a similar extent of ITH between various breast
cancers26,27. The global extent of ITH may hence not be a
suitable prognostic marker, not only for RCC but also for other
tumours. Nonetheless, our results encourage a more refined
approach to characterize ITH under inclusion of spatial
differences and intratumoural niches. In this context, it is
important to point out that there is heterogeneity even within
the peripheral zone, as shown by the finding that phospho-mTOR
S2448 and phospho-S6RP S235/236 occupied different areas
within the peripheral zone, that is, direct expression at the
invasion front and expression a few cell layers away from the
invasion front as shown in Fig. 6. This is remarkable since both
proteins can be phosphorylated by ribosomal S6 kinase 1 (ref. 28).
However, mTOR phosporylation has been implicated in a
negative-feedback loop28, and our finding may represent a
reflection of this regulatory mechanism.
Although we used HIF protein expression as surrogate for VHL
loss, it is noteworthy that the expression of HIF proteins is also
affected by other factors, for example, loss of chromosome 14q
that harbours the HIF1A gene. HIF protein expression has been
shown to be heterogeneous in the past8 and, furthermore, high
expression of HIF-1a has been reported at the invading edge of
malignant tumours similar to the results shown here29. HIF
overexpression has been linked to the loss of the adhesion
molecule E-cadherin30,31 resulting in an altered migratory
behaviour, which has recently been suggested as a key factor
for malignant progression14. Hence, potential effects of a
pharmacological inhibition of migratory behaviour of tumour
cells to prevent malignant progression deserve further attention.
Additional translational implications of our finding would be that
the use of an mTOR inhibitor could specifically target peripheral
zone cells with high proliferative capacity.
In summary, our results indicate the presence of topological
niches within single regions of primary ccRCCs that not only
harbour region-specific mutations but are also characterized by
tumour clones with unique functional properties. We provide
unexpected insights into the architecture of malignant tumours
and clonal evolution that have important implications for the
analysis of cancer genomes in general. An integrated analysis of
functional and genomic ITH appears to be required for a
comprehensive analysis and better understanding of cancer
genome evolution and malignant progression.
Methods
Tumours and immunohistochemistry. Formalin-fixed, paraffin-embedded
specimens from a total of 30 primary ccRCCs (Supplementary Table 1) were
retrieved from the archives of the Department of Pathology of the University of
Heidelberg School of Medicine under Ethics committee vota 206/2005 and
207/2005, and informed consent by the patients. Sections were deparaffinized in
xylene and rehydrated in a graded ethanol series. Antigen retrieval was performed
with a steam cooker using retrieval buffer (Target Retrieval Solution, Dako).
Primary antibodies used were as follows: HIF-1a (Novus Biologicals, H1alpha67,
NB100-105, 1:100), HIF-2a (Novus Biologicals, NB100-122, 1:100), phospho-
mTOR S2448 (Cell Signaling, 49F9, #2976, 1:100), phospho-S6RP S235/236 (Cell
Signaling, #2211, 1:50), Ki-67 (Dako, MIB-1, M7240, 1:100), CD31 (Dako, JC70A,
M0823, 1:100) and CD45 (Dako, 2B11þ PD7/26, M0701, 1:100). Immunodetec-
tion was performed using the Histostain-Plus Detection Kit (Invitrogen) according
to the manufacturer’s recommendations. The immunostaining for HIF-1a has been
validated in a previous study using a ccRCC with a deletion in exon 2 of the VHL
gene32.
Image quantification. Stained sections were scanned using a Nanozoomer 2.0-HT
Scansystem (Hamamatsu Photonics) to generate digital whole-slide images.
Quantification of the digital images was performed using the VIS software suite
(Visiopharm, Hoersholm, Denmark). To facilitate the comparison of identical
tumour regions stained on separate slides with different antibodies, adjacent tissue
sections were aligned and virtually segmented into squares of 1mm2 in size.
Staining results of each square were computed using either the PNC algorithm
(HIF-1a, HIF-2a and Ki-67) or the PPC algorithm (phospho-mTOR S2448 and
phospho-S6RP S235/236). The latter algorithm was designed to measure every
pixel per 1mm2 square based on its spectral characteristics. Non-cancerous regions
were excluded from quantification. Non-malignant cells within a cancerous area
(for example, endothelial cells or immune cells) were not excluded under the
assumption that the proportion of malignant versus non-malignant cells is
comparable across tumours. Staining results for each square were expressed as
either percentage positive nuclei or percentage positive pixels. If the 1mm2 square
had to be reduced because of non-cancerous parts, the percentage of positive pixels
was normalized to the corrected area. Staining results were then depicted as heat
maps.
To assess and compare heterogeneous staining, two different heterogeneity
scores were used. First, the s.d. that expresses the distribution of positivity of single
squares compared with average and, second, the difference between the maximum
and the average positive value of squares (MAX-m) which serves to highlight
outliers within a tumour area. For the purpose of validating the used heterogeneity
scores, we also applied two established biodiversity indices to our data set, that is,
the Shannon and inverse Simpson index. Both indices estimate biodiversity based
on the number of data categories s (¼ species) and the quantity of squares
(¼ individuals) of their respective data categories. To compare the biodiversity
indices between the five different biomarkers, data categories were defined
dependent on the range of % PP or % PN, respectively. % PN of HIF-1a and
HIF-2a range from 0 to 100% and 5% intervals were used to reach a maximum of
20 data categories per sample. % PP of phospho-mTOR S2448 and phospho-S6RP
S235/236 as well as % PN of Ki-67 range roughly from 0 to 25% and therefore 2%
intervals were defined to reach the same maximum of data categories (s¼ 20).
The Shannon index assumes that all data categories are represented in a given




pi ln pi ð1Þ
p is the proportion of squares of one specific data category, divided by the total
number of squares found in a given sample, and s is the number of data categories.
The inverse Simpson index gives more weight to common data categories.







The peripheral tumour zone was defined as outermost squares of each tumour.
Small lesions in which only two layers of squares were present (and hence by
definition no central zone; n¼ 3) were excluded from the analysis.
Whole-exome sequencing. DNA extraction and whole-exome sequencing were
performed by GATC Biotech (Konstanz, Germany) on an Illumina HiSeq 2500
platform (InView Human Exome). Fastq files were aligned against the human
reference genome (build 37, version hs37d5), using bwa mem (version 0.7.8 with
minimum base quality threshold set to zero [-T 0] and remaining settings left at
default values), followed by coordinate sorting with bamsort (with compression
option set to fast (1)) and marking duplicate read pairs with bammarkduplicates
(with compression option set to best (9); both part of biobambam package version
0.0.148).
The generated bam files were used to identify SNVs by applying samtools
mpileup33 (version 0.1.19 with parameter settings -REI -q 30 -ug) with output
piped to bcftools view (version 0.1.19 with parameters settings -vgN -p 2.0).
Determination of high-quality sample-specific SNVs was largely done as described
in ref. 34 with additional classification into 96 categories according to their triplet
of the base preceding the SNV, the actual transition/transversion and the following
base. For each class, it was determined whether its SNVs exhibit a sequencing
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strand bias. For classes with bias, SNVs with less than two supporting reads on the
strand opposite to the bias were filtered out. SNVs were called functional, when
they were nonsynonymous, occurred within splice sites or lead to gain or loss of
stop codons. For each category, SNV counts were determined and corrected for the
triplet distribution of the human exome using the genomic coordinates of the used
target capture kit (Agilent 5 without untranslated regions). Normalized counts
were grouped into the two different strata (central and peripheral) and analysed
both per patient to get eight patient-specific distributions and for all patients
together to get two strata-specific distributions. The distributions were compared
using pair-wise cosine similarity as previously described13.
Indels were identified using Platypus callVariants (version 0.8.1, parameter settings
genIndels¼ 1, genSNPs¼ 1, bufferSize¼ 1,00,000 and maxReads¼ 1,00,00,000)35.
All SNVs and indels were annotated using Annovar36 (version as of November
2014), dbSNP (Build 141)37, 1000 Genomes38 and EVS (Exome Variant Server,
NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (version ESP6500SI-
V2)) data.
Genome data are deposited at the European Genome-phenome Archive
(EGA, http://www.ebi.ac.uk/ega/), which is hosted at the EBI, under accession
number EGAS#00001001784.
Statistical analysis. The data are summarized as median±interquartile range.
The D’Agostino–Pearson omnibus test was used to determine whether the data
within are consistent with a Gaussian distribution. Statistical analyses were
performed with the Mann–Whitney, Kruskal–Wallis, Fisher exact test and Ber-
noulli trial, as appropriate. Bernoulli trial was used with probability of success of
0.51 because the number of squares in the tumour periphery versus the centre were
similar (4,475 versus 4,425). Statistical significance was accepted at values of
Po0.05. Correlation analyses were performed using Spearman correlation for
non-parametric variables. Degrees of correlation were considered as followed:
0.0–0.2 (no correlation), 0.2–0.4 (weak correlation), 0.4–0.7 (moderate-to-good
correlation) and 0.7–1.0 (good-to-very good correlation).
Data availability. Genome sequencing data are deposited at the European
Genome-phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted at
the EBI, under accession number EGAS#00001001784. All other relevant data
supporting the findings of this study are either included within the article and its
Supplementary Information files or available upon request from the corresponding
author.
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16. Tözeren, A., Coward, C. W. & Petushi, S. P. Origins and evolution of cell
phenotypes in breast tumors. J. Theor. Biol. 233, 43–54 (2005).
17. Baxter, L. T. & Jain, R. K. Transport of fluid and macromolecules in tumors. I.
Role of interstitial pressure and convection. Microvasc. Res. 37, 77–104 (1989).
18. Hlatky, L., Hahnfeldt, P. & Folkman, J. Clinical application of antiangiogenic
therapy: microvessel density, what it does and doesn’t tell us. J. Natl. Cancer
Inst. 94, 883–893 (2002).
19. Polyak, K., Haviv, I. & Campbell, I. G. Co-evolution of tumor cells and their
microenvironment. Trends Genet. 25, 30–38 (2009).
20. Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal
prostate cancer. Nat. Genet. 47, 736–745 (2015).
21. Brocks, D. et al. Intratumor DNA methylation heterogeneity reflects clonal
evolution in aggressive prostate cancer. Cell Rep. 8, 798–806 (2014).
22. Hong, M. K. H. et al. Tracking the origins and drivers of subclonal metastatic
expansion in prostate cancer. Nat. Commun. 6, 6605 (2015).
23. Cooper, C. S. et al. Analysis of the genetic phylogeny of multifocal prostate
cancer identifies multiple independent clonal expansions in neoplastic and
morphologically normal prostate tissue. Nat. Genet. 47, 367–372 (2015).
24. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas
delineated by multiregion sequencing. Science 346, 256–259 (2014).
25. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability
processes defines lung cancer evolution. Science 346, 251–256 (2014).
26. Almendro, V. et al. Genetic and phenotypic diversity in breast tumor
metastases. Cancer Res. 74, 1338–1348 (2014).
27. Almendro, V. et al. Inference of tumor evolution during chemotherapy by
computational modeling and in situ analysis of genetic and phenotypic cellular
diversity. Cell Rep. 6, 514–527 (2014).
28. Holz, M. K. & Blenis, J. Identification of S6 kinase 1 as a novel mammalian
target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280,
26089–26093 (2005).
29. Zhong, H. et al. Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59, 5830–5835 (1999).
30. Evans, A. J. et al. VHL promotes E2 box-dependent E-cadherin transcription by
HIF-mediated regulation of SIP1 and snail. Mol. Cell. Biol. 27, 157–169 (2007).
31. Langner, C., Ratschek, M., Rehak, P., Schips, L. & Zigeuner, R. Expression of
MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic
immunohistochemical analysis of 188 cases. Mod. Pathol. 17, 180–188 (2004).
32. Schneider, M. et al. Phenotypic drug screening and target validation for
improved personalized therapy reveal the complexity of phenotype-genotype
correlations in clear cell renal cell carcinoma. Urol. Oncol. 32, 877–884 (2014).
33. Li, H. et al. The sequence alignment/Map format and SAMtools. Bioinformatics
25, 2078–2079 (2009).
34. Vater, I. et al. The mutational pattern of primary lymphoma of the
central nervous system determined by whole-exome sequencing. Leukemia 29,
677–685 (2015).
35. Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based
approaches for calling variants in clinical sequencing applications. Nat. Genet.
46, 912–918 (2014).
36. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38,
e164 (2010).
37. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids
Res. 29, 308–311 (2001).
38. 1000 Genomes Project Consortium. An integrated map of genetic variation
from 1,092 human genomes. Nature 491, 56–65 (2012).
Acknowledgements
This work was supported by the Medical Faculty Heidelberg and, in part, by Novartis
Pharma GmbH. N.K. was supported by a post-doctoral fellowship from the Medical
Faculty Heidelberg. R.H. was supported by a fellowship ‘Talents in Medicine’ from the
Medical Faculty Heidelberg. D.H. is a member of the Hartmut Hoffmann-Berling
International Graduate School of Molecular and Cellular Biology and of the MD/PhD
program of the University of Heidelberg and is grateful to Michael Lanzer and Claudia
Denk for supervision and guidance.
Author contributions
R.H. helped to conceive the study, performed the immunostainings and quantitative
image analysis, analysed the results and participated in exome sequencing data analysis
and interpretation, figure preparation and writing of the manuscript. B.L. helped to
analyse the image analysis data. G.W. and D.H. performed the analysis of exome
sequencing data and mutational signatures. C.S. and X.C. performed some of the
immunostainings and helped to analyse the data. B.W., L.H. and S.M.-G. participated in
sample collection. Y.T., N.K., A.D., C.G., D.J., S.Pe., G.S., J.N.-D., S.I., G.H., D.T., B.H.,
S.Pa. W.R. and M.H. participated in sample collection, data interpretation, discussion
and supervision of the study. R.E., M.S., H.S. and N.G contributed to experimental
design, data analysis and gave critical advice for data interpretation. S.D. conceived the
study and participated in data analysis, interpretation and preparation of the manuscript.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11845 ARTICLE
NATURE COMMUNICATIONS | 7:11845 |DOI: 10.1038/ncomms11845 | www.nature.com/naturecommunications 11
Additional Information
Accession codes: The whole genome sequencing data have been deposited in the Eur-
opean Genome-phenome Archive (EGA, http://www.ebi.ac.uk/ega/) which is hosted at
the EBI, under accession code EGAS#00001001784.
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